Matthew Chun

Matthew Chun is a Senior Principal Scientist at Amgen, where since March 2016, responsibilities have included drug discovery and development within the Oncology department, specifically focusing on T cell engagers and bispecific antibodies. Matthew has led multiple oncology drug discovery programs, overseeing the design of experiments, validation of biological hypotheses, and delivery of therapeutic candidates for clinical development. Achievements include the nomination of four T cell engager programs and one bispecific antibody program, along with the delivery of a clinical candidate and a patent filing. Prior to Amgen, Matthew served in various roles at the Salk Institute for Biological Studies from November 2010 to February 2016, including Postdoctoral Fellow, developing small molecule inhibitors of the kinase ULK1. Matthew holds a Ph.D. in Cell Biology from the University of California, San Francisco, and an A.B. in Biochemistry from Harvard University.